Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas

Neurology

Volumn 63, Issue 5, 2004, Pages 904-906

  Triebels, V H J M ^a,b   Taphoorn, M J B ^c   Brandes, A A ^d   Menten, J ^e   Frenay, M ^f   Tosoni, A ^d   Kros, J M ^a   Biemond Ter Stege, E ^a   Enting, R H ^a   Allgeier, A ^g   Van Heuvel, I ^a   Van Den Bent, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f CENTRE ANTOINE LACASSAGNE   (France)

^g EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME 1P; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE PROBE; GENOTYPE; HUMAN; LEUKOPENIA; MALE; NAUSEA; OLIGODENDROGLIOMA; PRIORITY JOURNAL; RECURRENT CANCER; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 4644329614     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000137049.65631.DB     Document Type: Article

References (10)

1. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994;12:2013-2021.
2. van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology 1998;51:1140-1145.
3. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma: the European Organisation of Research and Treatment of Cancer Brain Tumor Group study 26971. J Clin Oncol 2003;21:2525-2528.
4. van den Bent MJ, Keime-Guibert F, Brandes AA, et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 2001;57:340-342.
5. Chinot O, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001;19:2449-2455.
6. van den Bent MJ, Chinot O, Boogerd W, et al. Second line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003;14:599-602.
7. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG. Salvage chemotherapy for oligodendroglioma. J Neurosurg 1996;85:597-601.
8. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
9. van den Bent MJ, Looijenga LHJ, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276-1284.
10. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Canc Res 2001;7:839-845.